Welcome to
the home page of the newest advanced immunological cancer therapy autologous vaccine AHICE.
K-BIO, Clinical Biochemical Institute for Cellbiotechnology and Immunology GmbH.
A LEADER IN THE RESEARCH AND DEVELOPEMENT OF AUTOLOGOUS IMMUNOLOGICAL CANCER- , AUTO-IMMUNE-DISEASES-TREATMENT as also for prevention by means of the AUTOLOGOUS HUMAN VACCINE (special kind of hemodialysis) AHICE - won out of patients own blood - complete cascade of autologous immune-response against the targeted tumour-cells - individual therapy.
IS SUCCESSFUL TUMOURTHERAPY POSSIBLE?
In 1995 the German-Carcinoma-Research-Center(DKFZ), Heidelberg, has examined statistically the therapeutical results earned by application of the conservative tumourtherapy on various kinds of tumours. In conclusion of that, the conservative tumourtherapy (that is the combined application of surgical tumour-removal + radiation + chemotherapy) decreases the chance of tumourpatients to survive down to a level of 5% (Origin: FOCUS, 19, 1995)[1]. This alarming bad therapy-result is equal with the global refusal of the conservative tumourtherapy, which is only trying to fight against the symptomatics of carcinoma, applicating celltoxic substances (that have a poor selectivity-ability), but not against the casualty of establishing carcinoma in the patient´s organism. By the force of applicated conservative tumourtherapy( i. e. cytostatics, or radiation, or both) especially patient´s immune-system will strongly depressed. In conjunction, bone marrow as stemmcell-reservoir, liver and kidney were damaged on the celltoxic influence of the applicated chemotherapy-schemata - radiation- and chemotherapy causes various toxic secondary effects, upon general recognition. In addition, the therapy costs are very high in relation to the doubtful therapy-results of the conservative tumourtherapy.
What other carcinoma-therapy methods, more efficient, selective and specific than the conservative carcinoma-therapy, can fight successful carcinomas over long terms?
Onkology-specialized scientists, all over the world are of one mind, that a successful fight against carcinoma basically will be possible only upon generation of appropriate immunologic tumour-therapyforms*. That means, a specific activation of patient´s immune-system against the altered tumourcells, including newest biological, immunological, molecular-biological methods and bioengineering*.
* Prof. Harald zur Hausen, DKFZ, see webpage www.dkfz.de, lecture on 29.October 1999, pages 2. and 6., suggests that the immunological Tumourtherapy will be the only one therapeutical method, which will bring now and in the future the most outstanding specific therapeutical effects. Quotation:"....The National Cancer Center of the United States of America calls five main-areas, out of that future pioneering developments for the cancer-research and -therapy have to be expected. These are:
the immune-biology and the immune-therapy - it meant to be like our autologous AHICE-therapy,
the cell-biology, the Genes-Science and the Genetics, the molecular Epidemiology and the Bioinformatics.
K-BIO Institute agrees with that conviction.
Even convinced of the immunological cancer-therapy as well, are: Prof. Unger, clinic for tumour biology, Freiburg, like also Prof. Debatin, children clinic Ulm, at an occassion of a TV documentation: * miracles are ...* , SWR, 25.11.01.
Cassian Yee and colleagues of the Fred Hutchinson cancer research centre in Seatle, USA, are at once convinced with that. They report a therapeutic-effect of 80% with their immunological cancer therapy: Welt am Sonntag, 46 (2002), medicine, p. 31.
On that thematics were carried out scientifically projects all over the world over the last three decades of years, to find out suitable tumourtherapy concepts on immunological basis. However, till now, there have been recorded only a few therapeutically successes and only for a few kinds of carcinomas. The reason for that failure is due to applicate only one, or a few, homologous synthesized, intermediate factors, instead of the whole complex cascade of the autologous synthesized, tumourcell specific immune-response-products of the activation-chain of patient´s own immune-system! On this key-relationship, K-BIO Institute has developed the highly tumourcell specific, active immunologic therapy "Autologous Vaccine AHICE, for active immune-therapy of tumours and tumour-aftercare", after a long term of immunological / biochemical scientifical and developmental work. This tumourtherapy is involving the whole complex immune-response-products-cascade, as result of the specific immune-response, which normaly, is autologous synthesized over a complete in vivo immune-stimulation. In practice, this tumourcell specific, autologous human immune therapy AHICE, has been proved on various carcinomas and carcinoma stages (international patent).
The in vivo effectiveness is being proved in clinical trials with co-operative institutions until now at various carcinomas.
Also remarkable therapy-results have been achieved on treatment of auto-immune-diseases, such as Hashimoto Thyreoiditis and Rheumatoid Arthritis, for example.
The autologous vaccine(special kind of hemodialysis) AHICE is synthesized individually because of the Autology, by the order of the patient´s responsible doctor -
Praxis für Immuntherapie Dr. med. Karl-Heinz Regele, Internist
Danzigerstr. 1
82194 Gröbenzell
Tel. 08142-580024
.
Furthermore Informations:
K-BIO Clinical Biochemical Institute for Cellbiotechnology and Immunology GmbH
Tel.:(0049)-(0)8142-52030, Fax:(0049)-(0)8142-580023
e-Mail: Info[at]-BIO.de
[1]Disclaimer next ==> about us
